AMPA receptor antagonist CFM-2 decreases survivin expression in cancer cells

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Domingo Sanchez Ruiz - , Ace Alzheimer Center Barcelona (Autor:in)
  • Hella Luksch - , Hochschulmedizin (Medizinische Fakultät und Universitätsklinikum), Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Marco Sifringer - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Achim Temme - , Klinik und Poliklinik für Neurochirurgie, Technische Universität Dresden (Autor:in)
  • Christian Staufner - , Universität Heidelberg (Autor:in)
  • Wojciech Rzeski - , Maria Curie-Skłodowska University in Lublin, Witold Chodźki Institute of Rural Medicine (Autor:in)
  • Jenny Marzahn - , Technische Universität Dresden (Autor:in)
  • Aneta Grabarska - , Medical University of Lublin (Autor:in)
  • Chrysanthy Ikonomidou - , University of Wisconsin-Madison (Autor:in)
  • Andrzej Stepulak - , Medical University of Lublin (Autor:in)

Abstract

Background: Glutamate receptors are widely expressed in different types of cancer cells. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors are ionotropic glutamate receptors which are coupled to intracellular signaling pathways that influence cancer cell survival, proliferation, and migration. Blockade of AMPA receptors by pharmacologic compounds may potentially constitute an effective tool in anticancer treatment strategies. Method: Here we investigated the impact of the AMPA receptor antagonist CFM-2 on the expression of the protein survivin, which is known to promote cancer cell survival and proliferation. We show that CFM-2 inhibits survivin expression at mRNA and protein levels and decreases the viability of cancer cells. Using a stably transfected cell line which overexpresses survivin, we demonstrate that over-expression of survivin enhances cancer cell viability and attenuates CFM-2–mediated inhibition of cancer cell growth. Result: These findings point towards suppression of survivin expression as a new mechanism contributing to anticancer effects of AMPA antagonists.

Details

OriginalspracheEnglisch
Seiten (von - bis)591-596
Seitenumfang6
FachzeitschriftAnti-cancer agents in medicinal chemistry
Jahrgang18
Ausgabenummer4
PublikationsstatusVeröffentlicht - 2018
Peer-Review-StatusJa

Externe IDs

PubMed 29493464

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • AMPA glutamate receptor, Antagonist, Cancer, Cells, CFM-2, Ionotropic glutamate receptors, Survivin